Evidence map›Paper›PMID 27841868›Full record

ArticleOncogene2017

Long noncoding RNA-SRLR elicits intrinsic sorafenib resistance via evoking IL-6/STAT3 axis in renal cell carcinoma.

Z Xu, F Yang, D Wei, B Liu, C Chen, Y Bao, Z Wu, D Wu, H Tan, J Li and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
70citing papers in PubMed, 2 pooled it
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

70 citing papers in PubMed, 2 syntheses or guidelines pooled it, 118 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article

10 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Z XuDepartment of Urology, Changzheng Hospital, Second Military Medical University, Shanghai, China.
F YangDepartment of Medical Genetics, Second Military Medical University, Shanghai, China.
D WeiDivision of Endocrinology, Department of Internal Medicine, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan, China.
B LiuDepartment of Urology, Changzheng Hospital, Second Military Medical University, Shanghai, China.
C ChenDepartment of Medical Oncology, Jinling Hospital, Nanjing University Clinical School of Medicine, Nanjing, China.
Y BaoDepartment of Urology, Changzheng Hospital, Second Military Medical University, Shanghai, China.
Z WuDepartment of Urology, Changzheng Hospital, Second Military Medical University, Shanghai, China.
D WuDepartment of Urology, Changzheng Hospital, Second Military Medical University, Shanghai, China.
H TanDepartment of Urology, Changzheng Hospital, Second Military Medical University, Shanghai, China.
J LiDepartment of Urology, Changzheng Hospital, Second Military Medical University, Shanghai, China.
J WangDepartment of Urology, Changzheng Hospital, Second Military Medical University, Shanghai, China.
J LiuDepartment of Urology, Changzheng Hospital, Second Military Medical University, Shanghai, China.
S SunDepartment of Medical Genetics, Second Military Medical University, Shanghai, China.
L QuDepartment of Urology, Changzheng Hospital, Second Military Medical University, Shanghai, China.
L WangDepartment of Urology, Changzheng Hospital, Second Military Medical University, Shanghai, China.
Second Military Medical University · CNNanjing General Hospital of Nanjing Military Command · CNShandong Provincial QianFoShan Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although the use of sorafenib appears to increase the survival rate of renal cell carcinoma (RCC) patients, there is also a proportion of patients who exhibit a poor primary response to sorafenib therapy. It is therefore critical to elucidate the mechanisms underlying sorafenib resistance and find representative biomarkers for sorafenib treatment in RCC patients. Herein, we identified a long non-coding RNA referred to as lncRNA-SRLR (sorafenib resistance-associated lncRNA in RCC) that is upregulated in intrinsically sorafenib-resistant RCCs. lncRNA-SRLR knockdown sensitized nonresponsive RCC cells to sorafenib treatment, whereas the overexpression of lncRNA-SRLR conferred sorafenib resistance to responsive RCC cells. Mechanistically, lncRNA-SRLR directly binds to NF-κB and promotes IL-6 transcription, leading to the activation of STAT3 and the development of sorafenib tolerance. A STAT3 inhibitor and IL-6-receptor antagonist both restored the response to sorafenib treatment. Moreover, a clinical investigation demonstrated that high levels of lncRNA-SRLR correlated with poor responses to sorafenib therapy in RCC patients. Collectively, lncRNA-SRLR may serve as not only a predictive biomarker for inherent sorafenib resistance but also as a therapeutic target to enhance responses to sorafenib in RCC patients.

Indexed as

Biomarkers, TumorCarcinoma, Renal CellCell Line, TumorDrug Resistance, NeoplasmGene Expression ProfilingHumansInterleukin-6Kidney NeoplasmsMicroarray AnalysisNiacinamidePhenylurea CompoundsRNA, Long NoncodingSignal TransductionSorafenibSTAT3 Transcription FactorBiomarkers, TumorInterleukin-6NiacinamidePhenylurea CompoundsRNA, Long NoncodingSorafenibSTAT3 Transcription Factor

Identifiers

PMID27841868
OpenAlexW2552236699

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.